Search results
Showing 211 to 225 of 490 results for %s
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.
there is a small risk that in some cases significant cancers may be missed, s o the committee recommended clinicians discuss the risk...
there is a small risk that in some cases significant cancers may be missed, s o the committee recommended clinicians discuss the risk...
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for HTG717Show all sections
Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)
NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .
In development Reference number: GID-TA10620 Expected publication date: 12 June 2026
NICE has developed a medtech innovation briefing (MIB) on Bindex for investigating suspected osteoporosis .
COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)
This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.
NICE has a developed medtech innovation briefing on Mollii suit for spasticity .
pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)
NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .
NICE has developed a medtech innovation briefing (MIB) on Airglove air warming system for venous access .
This quality standard covers the identification and management of familial and genetic risk and the recognition and management of ovarian, fallopian tube and primary peritoneal cancer or borderline ovarian cancer in women, trans men and non-binary people aged 18 and over with female reproductive organs (ovaries, fallopian tubes or a uterus). It describes high-quality care in priority areas for improvement.
View quality statements for QS18Show all sections
Sections for QS18
- Quality statements
- Quality statement 1: Discussion about risk-reducing surgery
- Quality statement 2 (placeholder): CA125 blood test – age-specific thresholds
- Quality statement 3: Panel germline genetic testing for non-mucinous high-grade epithelial ovarian cancer
- Quality statement 4: Tumour genetic testing for stage 3 or 4 non-mucinous high-grade epithelial ovarian cancer
- Quality statement 5: Treatment of high-risk stage 1 or stage 2 to 4 ovarian cancer
- Update information
- About this quality standard
This guideline covers safe midwifery staffing in all maternity settings, including at home, in the community, in day assessment units, in obstetric units, and in units led by midwives (both alongside hospitals and free-standing). It aims to improve maternity care by giving advice on monitoring staffing levels and actions to take if there are not enough midwives to meet the needs of women and babies in the service.
This guide describes the methods that NICE follows when evaluating interventional procedures. Processes for interventional procedures are in section 1 of the NICE HealthTech programme manual
Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-positive locally advanced or metastatic non-small-cell lung cancer in adults.